OBIO Stock Analysis: Buy, Sell, or Hold?
OBIO - Orchestra BioMed Holdings, Inc. Ordinary Shares
$5.95
-0.40 (-6.30%)
âŧ
5d:
+0.0%
30d:
+20.2%
90d:
+45.83%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 09, 2026
Get Alerted When OBIO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: OBIO is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: OBIO is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: OBIO is currently trading at $5.95, which is considered slightly high relative to its 30-day fair value range of $5.21 to $6.15.
Technical Outlook: Technically, OBIO is in a strong uptrend. Immediate support is located at $5.75, while resistance sits at $6.50. Short-term momentum is weak, with the stock down 6.3% recently.
Market Sentiment: OBIO scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $12.43 (+108.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, OBIO is in a strong uptrend. Immediate support is located at $5.75, while resistance sits at $6.50. Short-term momentum is weak, with the stock down 6.3% recently.
Market Sentiment: OBIO scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $12.43 (+108.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$5.21 -
$6.15
Company Quality Score
40/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.3%)
- BULLISH: Trading 108.9% below Wall St target ($12.43)
- WARNING: Composite score 40/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$5.21 -
$6.15
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
Âą$0.69
(11.6%)
Support & Resistance Levels
Support Level
$5.75
Resistance Level
$6.50
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.94
Wall Street Target
$12.43
(+108.9%)
Revenue Growth (YoY)
-89.5%
Profit Margin
-184.6%
Share & Embed Analysis
Last updated: October 03, 2026 3:00 AM ET
Data refreshes hourly during market hours. Next update: 4:00 AM
Data refreshes hourly during market hours. Next update: 4:00 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OBIO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 54 HOLD |
|
REGN
Regeneron PharmaceuticalâĻ |
STRONG BUY
25 analysts |
$851 | 48 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$293 | 67 BUY |
|
MLTX
MoonLake ImmunotherapeutâĻ |
STRONG BUY
16 analysts |
$29 | 49 HOLD |
|
ACAD
ACADIA Pharmaceuticals IâĻ |
BUY
20 analysts |
$32 | 62 BUY |
